Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Frequently asked questions
What sector does Adaptimmune Therapeutics Plc (ADAP) operate in?
Adaptimmune Therapeutics Plc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Adaptimmune Therapeutics Plc (ADAP) current stock price?
As of the latest data, Adaptimmune Therapeutics Plc stock price is $0.06, with a previous close of $0.06.
What is Adaptimmune Therapeutics Plc (ADAP) current market capitalization?
Adaptimmune Therapeutics Plc market cap is approximately 14.58 million.
What is Adaptimmune Therapeutics Plc (ADAP) Earnings Per Share (EPS)?
The trailing EPS is -$0.66, and the forward EPS is -$0.50.
Does Adaptimmune Therapeutics Plc (ADAP) pay dividends?
No. Adaptimmune Therapeutics Plc does not pay a dividend.
What is Adaptimmune Therapeutics Plc (ADAP) beta (volatility) score?
Adaptimmune Therapeutics Plc has a beta of 2.492, indicating very high volatility compared to the market.
Unfortunately, you do not have access to this data. Make sure you have an active subscription.
